AI tools for dermatology: lesion detection, dermpath, and teledermatology

May 6, 2026 · Pouyan Golshani, MD, Interventional Radiologist

Dermatology AI has the most validation data in lesion detection. Here’s the working directory. While the clinical applications are maturing rapidly, from automated melanoma screening to digital pathology, an equally powerful force is reshaping our specialty: the financial engineering applied by private equity. The same data-driven mindset that optimizes an algorithm is being used to optimize practice valuations and roll-ups. For the physician-owner, understanding the clinical tools is important, but mastering the financial playbook is critical for survival and long-term wealth. This article focuses on the strategic and tax implications of running a modern dermatology practice in the PE era. For a deeper dive into the clinical side, you can explore our full list of dermatology AI tools and resources or browse the comprehensive physician AI tools directory.

Structuring Your Private Equity Buyout for Tax Efficiency

Private equity’s appetite for dermatology is driven by predictable cash flow, elective procedures, and opportunities for consolidation. If you’re a practice owner, an offer from a PE-backed group is a matter of when, not if. The headline number they offer is seductive, but the real financial outcome is determined by the deal structure, specifically whether it’s an asset sale or a stock sale.

Most of us assumed a sale is a sale. The hard way to learn you’re wrong is on tax day. PE buyers almost always push for an asset sale. This structure benefits them immensely: they get to “step-up” the basis of the assets they acquire (your equipment, building, etc.) to the purchase price, allowing them to claim larger depreciation deductions going forward. For you, the seller, it’s often a tax disaster.

In an asset sale, the purchase price is allocated among the different assets. The portion allocated to your hard assets (lasers, exam chairs) is subject to depreciation recapture and taxed as ordinary income. The amount allocated to patient accounts receivable is also ordinary income. The only part that gets favorable long-term capital gains treatment is the goodwill. It’s common for a huge chunk of the sale price to end up being taxed at top marginal rates (37% federal plus state) instead of the long-term capital gains rate (20% federal plus state).

The alternative is a stock sale (if your practice is a C-corp or S-corp). Here, you sell your shares in the practice entity. The entire gain is typically treated as a long-term capital gain, assuming you’ve owned the stock for more than a year. This is vastly preferable for the seller. The buyer doesn’t get the depreciation benefits of an asset sale, which is why they resist it. The key takeaway: the negotiation over asset versus stock sale structure can be worth more than a 10-20% bump in the sale price. Don’t let the headline number distract you from the after-tax reality.

Equity Rollover Deal Mechanics: Deferring Tax and Retaining Upside

In many PE deals, the offer isn’t all cash. A common structure involves taking a significant portion of your payment as equity in the new, larger parent company—the “NewCo.” This is known as an equity rollover. For example, on a $10 million sale, you might be offered $7 million in cash and $3 million in NewCo stock.

The primary benefit of the rollover is tax deferral. Under IRS Section 351 or similar provisions, the exchange of your old practice stock for NewCo stock is generally not a taxable event. You only pay tax on the cash portion of the deal immediately. The tax on the $3 million in rolled equity is deferred until a future “second bite of the apple”—when the PE firm sells the entire NewCo to another buyer, typically 5-7 years down the line.

This has two major implications:

Tax Deferral: You keep more capital invested and working for you. Instead of paying capital gains tax on the full $10 million, you only pay it on $7 million. The tax liability on the other $3 million is pushed years into the future.
Retained Upside: You are now a minority owner in a much larger, professionally managed entity. If the PE firm successfully executes its growth strategy—acquiring more practices, increasing efficiency, and boosting EBITDA—your rolled equity could be worth significantly more at the next sale. A 2-3x return on the rolled portion is often the target.

However, this comes with a critical planning trap: concentration and illiquidity. You are exchanging liquid cash for illiquid, private stock in a highly leveraged company. If the PE firm’s strategy fails, that stock could be worth zero. You have no control and no market to sell your shares. The decision of how much equity to roll over is a delicate balance between tax optimization, potential upside, and your personal risk tolerance. Taking less cash means more potential gain but also more risk concentrated in a single, illiquid asset tied to your former industry.

R&D Tax Credits for Proprietary Products and Software

When physicians hear “R&D tax credit,” they think of pharmaceutical companies or biotech startups. Most have no idea that their own clinical practice might qualify. Under Internal Revenue Code §41, the Research and Development Tax Credit is designed to reward companies for developing new products, processes, or software. Many activities inside a modern dermatology practice fall squarely into this category.

Consider these common scenarios:

Proprietary Skincare Compounds: Do you work with a compounding pharmacy to develop unique formulations for your patients? The process of testing different bases, active ingredient concentrations, and preservatives to improve efficacy or reduce irritation is a qualifying research activity.
Improving Clinical Processes: Have you developed a new, systematic protocol for a cosmetic procedure to improve outcomes and reduce side effects? The time spent documenting, testing, and refining this process can qualify.
Internal Software Development: Did you hire a developer or use your own time to build a custom module for your EMR to better track outcomes for psoriasis patients on biologics? Or perhaps a tool to analyze before-and-after photos for cosmetic procedures? This is a classic example of developing internal-use software, which qualifies for the credit.

The credit is calculated based on qualified research expenses (QREs), which include the wages of the staff involved in the research (including a portion of your own), supplies used, and costs for any outside contractors. The documentation is key. You need to be able to show that you were attempting to eliminate uncertainty and engaged in a process of experimentation. Most practices simply fail to track these activities. The planning trap is assuming you don’t qualify. By implementing a system to contemporaneously document these innovative activities, you could be claiming a credit worth tens of thousands of dollars each year against your practice’s income tax.

Practice Valuation Drivers and EBITDA Multiples

Private equity firms don’t value your practice based on revenue or patient volume. They value it based on a multiple of EBITDA—Earnings Before Interest, Taxes, Depreciation, and Amortization. This is a proxy for the practice’s operating cash flow and profitability. A practice with $5 million in revenue and $1 million in EBITDA might be valued at 8x, or $8 million. Another practice with the same revenue but $1.5 million in EBITDA could command a 10x multiple, valuing it at $15 million.

Understanding what drives both the EBITDA number and the multiple is the key to maximizing your practice’s enterprise value. It’s not about working harder; it’s about building a more valuable business.

Key drivers that increase your EBITDA multiple:

Recurring Revenue: A PE buyer sees a patient who comes in for a one-off cosmetic treatment as transactional. A patient signed up for a “skin health membership” that provides a monthly facial and discounts on products is recurring revenue. This is far more valuable and predictable, commanding a higher multiple.
Provider Mix and Scalability: A practice heavily dependent on the owner’s personal production is risky. A practice with a diversified team of dermatologists, PAs, and aestheticians, all working efficiently, is a scalable platform.
Ancillary Services: Integrating high-margin services like a medical spa, a skincare product line, or even an in-house pathology lab dramatically increases profitability per patient. Retail product sales, in particular, can significantly boost EBITDA.
Geographic Concentration: For a PE firm looking to build a regional powerhouse, a practice with a dominant market share in a desirable metro area is worth more than an isolated rural practice.

The trap many physicians fall into is optimizing for personal income, not enterprise value. They might pay themselves a large salary, run personal expenses through the business, and fail to invest in systems that create recurring revenue. This deflates the official EBITDA. Before considering a sale, you should spend 12-24 months “cleaning up” your financials to maximize EBITDA and demonstrate the recurring nature of your cash flow. Knowing what buyers pay for allows you to decide whether you want to build a cash-flow machine for yourself or a valuable asset to sell.

The 199A QBI Deduction: A Tax Break Most Dermatologists Can’t Take

The Tax Cuts and Jobs Act of 2017 introduced Section 199A, the Qualified Business Income (QBI) deduction. It was heralded as a major tax break for owners of pass-through businesses (S-corps, partnerships, sole proprietorships), allowing them to deduct up to 20% of their business income. For a physician with $500,000 in practice income, this sounds like a $100,000 deduction. Unfortunately, for most successful dermatologists, this is a mirage.

The law includes a major exception for any “Specified Service Trade or Business” (SSTB). This category explicitly includes the field of medicine. While being an SSTB doesn’t automatically disqualify you, it subjects you to a strict income limitation. For 2026, the QBI deduction for an SSTB begins to phase out at a taxable income of approximately $394,000 for single filers and $787,000 for those married filing jointly. It disappears completely above these levels.

Let’s be realistic. A successful dermatologist, especially a practice owner, will almost certainly have a taxable income far exceeding these thresholds. A physician with $600,000 in practice profit and a spouse who earns $200,000 has a joint income of $800,000, placing them squarely in the phase-out range. The planning trap is building a financial plan assuming you’ll receive this 20% deduction. For the vast majority of physicians, the effective QBI deduction is zero.

This reality check is crucial. Instead of chasing a deduction you can’t get, your time is better spent focusing on strategies that are actually available to high-income professionals. This includes maximizing contributions to tax-deferred retirement accounts like a 401(k) with a profit-sharing component, or even more advanced structures like a cash balance plan, which can allow you to shelter an additional six figures of income from tax each year. The 199A deduction was not designed for us; it’s critical to focus your tax planning on the rules that are.